Navigation Links
MacroGenics Raises $25M in Series D-2 Financing
Date:9/25/2008

y DART (Dual Affinity Re-Targeting) and Fc-optimization technologies offer ways to improve the function of antibodies and similar molecules. For more information about MacroGenics, please visit http://www.macrogenics.com.

About New Investors

Nextech Venture is a global healthcare investment manager located in Zurich, Switzerland. The firm manages three healthcare venture funds (USD 137M), and has recently launched the world's first oncology-focused fund. With its unique oncology-focused fund, Nextech Venture is a dedicated investor in leading oncology companies developing cancer drugs in Europe, the U.S. and Asia. Nextech Venture benefits from the support of an active and committed Scientific Advisory Board of highly influential oncology advisors. Nextech Venture organizes the Global Oncology Venture Event which is held annually in major cities around the globe. For more information, visit http://www.nextechventure.com.

Arcus Ventures consists of a team of professionals with experience in clinical oncology and academic medicine, drug development, hospital management, healthcare industry consulting and private equity. Arcus Ventures is dedicated to investing in oncology focused companies with innovative biopharmaceuticals and or new drug delivery product(s) that have pre-marketing approval and service companies with revenue. For more information, visit http://www.arcusventures.com.

Innovis Investments, located in Irvine, California and Brisbane, Australia, manages and advises two life science funds with focus on private and public companies in Biotechnology, Pharmaceuticals and Healthcare. Innovis Investments has a diverse and integrated team with a strong operational presence in the U.S. and Pacific Rim countries where half of its portfolio companies are located. Innovis
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Acquires Raven Biotechnologies
2. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
3. Yongye Biotechnology International Raises $9.4 Million in Private Placement
4. Proteolix Raises $79 Million in Series C Financing
5. Bacon Eating Contest Raises Money for American Heart Association
6. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
7. Pacific Biosciences Raises $100 Million to Fund Commercial Product Development
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. BSP Raises $2.6 Million Dollars From Private Investors
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... defines and segments the bio-based advanced phase change ... of revenue. , Browse through the TOC of ... report to get an idea of the in-depth ... the segmentation in the Asia-Pacific bio-based advanced phase ...
(Date:10/18/2014)... 18, 2014 The Asia-Pacific Liquid Crystal ... the concerned market in Asia-Pacific with analysis and forecast ... in 2013, and is expected to reach $380.0 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3
... ... Developers , ... March 4, 2010 -- This seminar details the fast-growing GenomeQuest sequence data management (SDM) platform ... discussion, and startup to Free Basic Account. , , ,When: March 17, 2010 ...
... , ... ... ... ...
... ... ... ... ...
Cached Biology Technology:GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 33Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials 2
(Date:10/15/2014)... rapidly and to an unexpected extent. The outbreak does ... the virus shows a new disease dynamic in regions, ... reason, the German National Academy of Sciences Leopoldina, acatech ... the Union of the German Academies of Sciences and ... today. , In the statement the academies call for ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... City & Toronto, January 6, 2013For individuals with agonizing pain, ... causes more pain. Adults and children whose pain gets worse ... based on research published in the January 6 on-line edition ... a molecular pathway by which morphine can increase pain, and ...
... SECURITY -- Thwarting threats . . . Many ... in Oak Ridge Jan. 8-12 for the inaugural Cyber Sciences ... Richard Clarke, author of "CYBER WAR: The Next Threat to ... the agenda are four plenary panels, 44 research talks and ...
... altering the way cancer is diagnosed and treated, but traditional ... the message delivered this week in a column appearing in ... JAMA ) by Scripps Clinic physicians Eric Topol, Kelly Bethel ... serves as chief academic officer of Scripps Health and director ...
Cached Biology News:The pain puzzle: Uncovering how morphine increases pain in some people 2The pain puzzle: Uncovering how morphine increases pain in some people 3January 2013 story tips from Oak Ridge National Laboratory 2Scripps physicians call for change in cancer tissue handling 2
... II RNA gel stain is a sensitive ... when bound to RNA and low background in ... formaldehyde/agarose or polyacrylamide gels using laser scanners or ... A 500 µL unit size (S-7564) and a ...
... Glutathion-S-Transferase-pi EIA Principle: ... enzymes, which are involved in the ... in 5 subgroups: Alpha, Mu, Pi, ... in their physiochemical, immunological, enzymatic and ...
... screening and binding optimization and built on ... synthesis platform. These microarrays are available as ... Service. Probe Content Our ... than 1500 known aptamer sequences. Add up ...
... comprehensive service for custom peptide microarray ... synthesized on Paraflo microfluidic chips for ... serum samples. This comprehensive service includes ... assays using sample(s) provided by you, ...
Biology Products: